Plasmodium vivax malaria: parasite biology defines potential targets for vaccine development.
Although progress in the development of an antimalarial vaccine has been mostly obtained through the study of P. falciparum, significant advances have recently been made in the study of P. vivax, the other major human malarial parasite. Antigens which have been shown to be important in P. falciparum have been characterized and in some cases cloned in P. vivax. Other studies have examined some of the more specific biological characteristics of P. vivax. Among these are studies on components present in caveolae--vesicle complexes of the infected erythrocyte, on the occurrence of delayed hepatic development leading to relapse, or on the Duffy erythrocyte antigen as a key receptor for parasite invasion. Although progress has been made in the short-term in vitro maintenance of P. vivax, the inability to maintain the parasite in continuous culture led to the investigation of wild parasite populations in patients; occurrence of extensive antigenic and karyotype polymorphism was detected in this way, as was a double-blocking and enhancing activity of human antibodies on parasite development in the vector. The association of monoclonal antibodies with DNA recombinant technology allowed the characterization of a number of P. vivax antigens to be made. Among these, an antigen shared between sexual and asexual stages was shown to constitute a target for transmission-blocking immunity. The cloning of an antigen involved in transmission-blocking immunity, along with that of the surface antigen of the sporozoite (CSP) and of a major surface antigen of the invasive merozoite (PV200) constitutes a significant step towards the development of a multivalent recombinant vaccine against P. vivax.
David
P H
PH
Unité d'Immunoparasitologie, Institut Pasteur, Paris, France.
del Portillo
H A
HA
Mendis
K N
KN
D000818:Animals; D006790:Host-Parasite Interactions; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D010966:Plasmodium vivax / Q000502:physiology*; D014612:Vaccines; D014614:Vaccines, Synthetic
D014612:Vaccines; D014614:Vaccines, Synthetic